10/28/2026
Ibogaine by David Dardashti marks 16 years in addiction treatment
The center reaffirms its mission with refined ibogaine protocols.
Topic archive
psychedelics
26 stories
10/26/2026
FDA psychedelics docket draws mixed stakeholder responses
Stakeholders express varied opinions on FDA's recent psychedelics docket, highlighting diverse perspectives.
10/26/2026
Trump administration considers psychedelics for veterans
Proposal aims to address PTSD in veterans using psychedelic treatments.
10/21/2026
Psychedelics and Silicon Valley: A new frontier
Psychedelics shift from counterculture to tech industry darling, reshaping capitalism.
10/21/2026
Matt Zorn on ibogaine, psychedelics policy at HHS
Matt Zorn discusses his transition from legal adversary to HHS official.
10/20/2026
Psychedelics fast-tracked by FDA under Trump order
Executive order allocates $50 million for psychedelic drug development, including ibogaine.
10/14/2026
Ibogaine's potential in addiction treatment faces cardiac risks
New review highlights ibogaine's promise and dangers in addiction therapy.
10/13/2026
Cannabis and psychedelics sector weekly roundup
Market Exclusive highlights recent developments in cannabis and psychedelics.
10/9/2026
Peaking documentary explores psychedelic healing
Film offers rare insight into psychedelic therapy for trauma and addiction.
10/6/2026
FDA seeks public input on ibogaine research
A request for information asks researchers, clinicians and the public how ibogaine trials should be designed, dosed and monitored.
10/6/2026
Trump explores psychedelic mental health treatments
Former President Trump reportedly interested in psychedelic therapies for mental health.
10/1/2026
Ibogaine, 5-MeO-DMT linked to higher adverse effects
Study finds increased health risks with ibogaine and 5-MeO-DMT use compared to other psychedelics.
9/30/2026
Adverse health outcomes of ibogaine, psychedelics studied
New study examines health risks of ibogaine and other psychedelics.
9/24/2026
Documentary explores real psychedelic experiences
Peaking offers a raw look at psychedelics' impact on mental health.
9/23/2026
Clearmind Medicine files US patents for psychedelic combinations
New patent applications aim to enhance mental health treatments using LSD, ketamine, ibogaine.
9/18/2026
Psychedelics Week highlights policy discussions in D.C.
Washington D.C. hosts key dialogues on psychedelics' future.
9/13/2026
Potential FDA approval of psychedelics impacts Japan
FDA approval of psychedelics like ibogaine could influence Japanese pharmacy practices.
9/4/2026
Federal report urges states to prepare for psychedelics
States advised to anticipate FDA approval of psychedelics for medical use.
8/21/2026
University of Miami gifts ibogaine application to Trump admin
The move could expedite psychedelic research for veteran treatment.
8/21/2026
Johnson & Johnson invests in Delix Therapeutics
Investment in neuroplastogen company highlights growing interest in non-hallucinogenic psychedelics.
8/14/2026
Veterans Affairs advances federal psychedelics push
New FDA guidance aligns with Veterans Affairs' psychedelics initiatives.
8/8/2026
SAMHSA gathers experts on psychedelics
AtaiBeckley and Compass Pathways explore new opportunities.
8/7/2026
Ibogaine gains traction among conservative leaders
Rick Perry and Bryan Hubbard lead efforts to legitimize ibogaine in Texas.
7/28/2026
Designing defensible protocols for psychedelics
Focus on documentation, training, and informed consent
7/17/2026
Ibogaine's long-term brain effects explored
Psychedelics like ibogaine may offer lasting brain changes.
7/15/2026
Royal Ontario Museum hosts psychedelics exhibit
Exhibit explores the evolving role of psychedelics in culture and medicine.